Introduction {#Sec1}
============

Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is often associated with the expression of (membrane) transport-associated multidrug resistance (MDR) proteins. Expression of P-glycoprotein (P-gp), encoded by the *MDR1* gene, is an independent adverse prognostic factor for response and survival in de novo AML \[[@CR1]--[@CR4]\]. Moreover, it has been shown that besides P-gp, also the MDR-related protein (MRP1/ABCC1) and the lung resistance-related protein (LRP), also designated as the major vault protein (MVP), are expressed in AML. However, the prognostic significance of the latter resistance proteins has not been settled \[[@CR3], [@CR5]--[@CR7]\]. Some years ago, a new drug resistant protein, i.e., the breast cancer resistance protein (BCRP/ABCG2), which is the equivalent of the mitoxantrone (MXT) resistant protein and the placental ABC transporter (ABCP), was found to be expressed in AML \[[@CR8]--[@CR13]\]. The precise role of either resistance proteins among poor risk AML such as in patients of older age has not been established. This study prospectively investigated the relevance of *MDR1*, *MRP1*, *LRP*, and *BCRP* messenger RNA (mRNA) expression in combination with known prognostic characteristics like CD34 expression, white blood cell (WBC) count, and secondary AML as possible denominators of response and survival in patients with AML aged 60+ who were treated in the same clinical trial.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

A group of 154 patients with AML aged 60 years or older were included in the present study. All patients were enrolled between May 1997 and February 1999 in an international, multigroup, randomized phase 3 trial performed under auspices of the Dutch--Belgian Hemato-Oncology Cooperative Group and the UK Medical Research Council \[[@CR14]\]. In that trial, 419 eligible white patients ≥60 years with previously untreated de novo and secondary AML (M0--M2 and M4--M7 according to the French--American--British \[FAB\] classification \[[@CR15]\]) were randomized to receive two cycles of induction chemotherapy consisting of daunorubicin (DNR) and cytarabine (ara-C) with or without the P-gp inhibitor PSC-833 (Valspodar, Amdray®; Novartis Pharma, Basle, Switzerland). Patients in both arms in complete remission after these two cycles were to receive one consolidation consisting of ara-C, MXT, and etoposide. Inclusion criteria, clinical characteristics, treatment, and outcome of the phase 3 trial have been previously reported \[[@CR14]\].

Bone marrow (BM) aspirates had been collected at diagnosis for the analysis of P-gp function and expression, as described previously \[[@CR14]\]. Selection of patients for our study was based on availability of sufficient purified AML blast samples in our tissue bank, which was the case for 154 patients.

This study was approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before randomization.

Methods {#Sec4}
-------

BM aspirates were obtained in heparinized tubes. Mononuclear BM cells were collected by Ficoll Hypaque density gradient centrifugation (density 1.077 g/m^3^; Pharmacia, Uppsala, Sweden). To obtain purified samples with more than 85% of blasts, T-cell depletion and adherence depletion was performed as previously described \[[@CR16]\]. Cells were cryopreserved in Dulbecco modified Eagle medium (DMEM; Gibco, Paisley, UK) supplemented with 10% dimethyl sulfoxide (Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS; Gibco) and stored in liquid nitrogen. On the day of the experiments, BM cells were thawed. Cells were washed and resuspended in DMEM supplemented with 10% FCS. Before RNA and DNA isolation, cells were washed with phosphate-buffered saline (Gibco).

MDR1, MRP1, LRP, and BCRP mRNA analysis {#Sec5}
---------------------------------------

The drug resistance proteins were analyzed using the methods that we previously reported \[[@CR11]\]. In brief, total RNA was isolated using the TRISOLV™ extraction as described by the manufacturer (Biotecx, Houston, TX). RNA was aliquoted and stored at −80°C. RNA samples were analyzed for RNA integrity by gel electrophoresis. cDNA was synthesized by the use of the TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA), diluted, aliquoted, and stored at −80°C. Quantitative RT-PCR was used to measure the mRNA expression levels of *MDR1*, *MRP1*, *LRP*, and *BCRP* by Taqman-chemistry on an ABI PRISM 7700 sequence detector (Applied Biosystems) using two endogenous reference genes, i.e., glyceraldehyde-3-phosphate dehydrogenase and porphobilinogen deaminase.

Definition of endpoints {#Sec6}
-----------------------

The clinical endpoints have been defined previously \[[@CR14]\]. In brief, complete response (CR) was defined as a normocellular BM with \<5% blasts, no Auer rods, and no evidence of extramedullary involvement. Because data on peripheral blood recovery within 60 days were not always available, they were not considered as a criterium for CR. Patients who relapsed or died within 28 days after CR were considered as not having achieved a CR. Event-free survival (EFS) was calculated from the date of randomization until no CR on induction therapy, relapse after CR, or death in CR, whichever came first. Patients who did not reach CR were considered failure for EFS at 1 day after randomization. Disease-free survival (DFS) was determined for all patients who achieved CR on induction therapy and was calculated from the date of CR until relapse or death, whichever came first. Overall survival (OS) was measured from randomization until death from any cause. Patients who were still alive at the date of last contact were then censored.

Statistical analysis {#Sec7}
--------------------

The original phase 3 trial had been designed to detect with a power of 80% an increase in 2-year EFS from 9.5% in the control arm (without PSC-833) to 18% in the PSC-833 arm (two-sided significance level *α* = 0.05) and included 419 eligible patients.

mRNA data were obtained from a subset of 154 patients with sufficient BM samples in our tissue bank available for analysis. Baseline parameters of interest were *MDR1*, *MRP1*, *LRP*, and *BCRP* mRNA expression. Clinical endpoints were CR rate, EFS, DFS, and OS.

Baseline characteristics of patients with or without mRNA expression data available were compared using the Fisher exact test or the Pearson *χ*^2^ test in case of discrete variables, whichever appropriate, or the Wilcoxon rank-sum test in case of continuous variables. The association between patient baseline characteristics and mRNA expression levels was analyzed using the Pearson *χ*^2^ test of the Spearman rank correlation test, whichever was appropriate. The prognostic value of mRNA levels with respect to CR rate was determined using logistic regression \[[@CR17]\] whereas the impact of *MDR1*, *MRP1*, *LRP*, and *BCRP* on EFS, DFS, and OS was analyzed with Cox regression analysis \[[@CR18]\]. For this purpose, the natural logarithm of the mRNA expression levels of the four resistance genes were included in the analyses because of the very skewed distribution of the original mRNA levels. In addition, the outcome of patients with coexpression of *MDR1* and *BCRP* was evaluated to confirm the poor prognosis of AML with *MDR1*/*BCRP* coexpression reported by Benderra et al. \[[@CR19]\] in patients with a median age of 45 years or older. These patients were defined as having mRNA levels of these two drug resistance genes equal to or higher than the median. Their outcome was compared to the other patients with at least one of the *MDR1* and *BCRP* mRNA expression levels below the median. Logistic regression and Cox regression analyses were performed unadjusted, as well as adjusted for other prognostic factors, i.e., secondary AML, natural logarithm of WBC count, square root of percentage CD34^+^ cells, and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), as well as for treatment arm in the phase 3 trial, as about half of the patients had been randomized to receive PSC-833 in addition to their chemotherapy. Kaplan--Meier curves \[[@CR20]\] were generated to illustrate survival and were compared using the log-rank test \[[@CR21]\]. All reported *p* values are two-sided and, in view of the exploratory nature of these analyses, were calculated without adjustment for multiple testing. *p* values ≤ 0.05 were considered statistically significant.

Results {#Sec8}
=======

In the phase 3 trial, a total of 419 untreated patients with AML aged 60 years and older were randomized to receive two induction cycles with or without PSC-833. As reported, no difference was found between both treatment arms as regards CR rate (54% in the PSC-833 arm versus 48% in the control arm, *p* = 0.22), 5-year EFS (7 versus 8%, *p* = 0.53) nor DFS (13 versus 17%, *p* = 0.06) and OS (10% in both arms, *p* = 0.52) \[[@CR14]\]. We previously reported the role of functional MDR1 expression with respect to clinical outcome in these patients.

In 154/419 of the patients, sufficient BM cells were available in our tissue bank to investigate the mRNA expression level of the drug resistance genes *MDR1*, *MRP1*, *LRP*, and *BCRP*. This subgroup consisted of a representative group according to age, gender, CD34 expression, cytogenetics, and FAB classification (Table [1](#Tab1){ref-type="table"}). In this test group, a higher WBC count at diagnosis was observed than in the other 265 patients, and relatively more patients had been randomized to the PSC-833 arm (57 versus 45%, *p* = 0.02). There was no significant difference in the levels of *MDR1*, *MRP1*, *LRP*, nor *BCRP* mRNA expression between the two treatment arms (data not shown). The CR rate and survival endpoints were also similar in both patient groups (Table [1](#Tab1){ref-type="table"}). However, patients with mRNA data in the PSC-833 arm had a higher CR rate (61 versus 40%, *p* = 0.02), whereas this was 54 versus 48% (*p* = 0.22) in all 419 patients. Table 1Comparison between patients with or without data available for expression of the drug resistance genes Drug resistance genes evaluated Yes *N* (%)No *N* (%)Total *N* (%)*p*Number of patients154265419Patient characteristicsMedian age, (range)67 (60--85)68 (58--85)67 (58--85)0.52Sex0.26 Male86 (56)163 (62)249 (59) Female68 (44)102 (38)170 (41)Secondary AML31 (20)73 (28)104 (25)0.09Median WBC count (×10^9^/l; range)19.1 (0.1--389)5.6 (0.5--300)8.9 (0.1--389)0.001*N*146243389Median % CD34^+^, (range)32.5 (0.1--97.9)29.7 (0.1--93.7)30.3 (0.1--97.9)0.50*N*152157309Cytogenetic risk classification^a^0.12 Favorable3 (3)2 (1)5 (2) Intermediate90 (80)132 (73)222 (76) Unfavorable19 (17)47 (26)66 (23) No data42 (n.i.)84 (n.i.)126 (n.i.)Treatment arm randomized0.02 DNR/ara-C66 (43)145 (55)211 (50) DNR/ara-C +PSC-83388 (57)120 (45)208 (50)Treatment outcomeCR rate, % (95% CI)52 (44--60)50 (44--56)51 (46--56)0.73EFS, % (95% CI)0.72 1 year23 (17--30)23 (18--28)23 (19--27) 5 years9 (5--14)7 (4--11)8 (5--11)DFS, % (95% CI)0.81 1 year38 (27--48)39 (31--48)39 (32--45) 5 years17 (10--26)14 (9--21)15 (11--21)OS, % (95% CI)0.31 1 year42 (34--50)41 (35--46)41 (36--46) 5 years14 (9--20)8 (5--12)10 (7--14)The results indicate that, apart from WBC count, there are no differences between the two subgroups.*N* number of patients with data (if not available for all patients); *n.i.* not included when calculating percentages^a^Classification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk \[[@CR14]\].

The mRNA expression levels of the resistance genes were not significantly associated with the age of the patients (Table [2](#Tab2){ref-type="table"}). *MRP1* and *LRP* expression showed a strong positive correlation with WBC count. Negative associations of *MDR1* and *BCRP* with WBC count were observed. A significant positive association was found between CD34 and *MDR1* and also with *BCRP* mRNA expression. No significant correlation was found between *MRP1* nor *LRP*, and CD34 expression (Table [2](#Tab2){ref-type="table"}). Interestingly, secondary AML cases had a significantly higher expression of *BCRP* (*p* \< 0.05) and lower *MRP1* and *LRP* levels (both *p* \< 0.01, Table [2](#Tab2){ref-type="table"}). In the vast majority of our patients, also P-gp efflux and expression data were available. Function and expression data and *MDR1* mRNA expression levels were highly correlated (*p* \< 0.001), which was published recently \[[@CR22]\]. Table 2Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and *MDR1*/*BCRP* coexpression mRNA expression of*MDR1MRP1LRPBCRPMDR1*/*BCRP* coexpressionCharacteristic Age0.15−0.01−0.090.090.07(153)(153)(153)(137)(147) Secondary AML0.06−0.22\*\*−0.21\*\*0.19\*0.12(153)(153)(153)(137)(147) WBC count−0.17\*0.28\*\*\*0.36\*\*\*−0.36\*\*\*−0.35\*\*\*(145)(145)(145)(131)(139) CD34^+^0.54\*\*\*0.14−0.080.17\*0.27\*\*(151)(151)(151)(135)(145) Unfavorable0.11−0.05−0.23\*0.130.10 Cytogenetic risk(111)(111)(111)(98)(106)Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001

In this cohort of patients of higher age with AML, *MDR1* and *BCRP* were highly associated (*p* \< 0.001), just as were *MRP1* and *LRP* mRNA (*p* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}). A negative association was found between *BCRP* and *MRP1* and between *BCRP* and *LRP* (both *p* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}). The 40 patients with coexpression of *BCRP* and *MDR1* had significantly higher CD34 expression (median 39.5% \[range 0.1--97.7%\] versus 25.9% \[range 0.1--97.9%\]; *p* = 0.001) and a lower WBC count (median 4.5 \[range 0.8--300\]×10^9^/l versus 28.1 \[range 0.1--389\]×10^9^/l; *p* \< 0.001). No significant correlation of *MDR1*, *BCRP*, or coexpression of *MDR1* and *BCRP* was found with unfavorable cytogenetics (*p* = 0.4; Table [2](#Tab2){ref-type="table"}). Fig. 1Association between *MDR1*, *MRP1*, *LRP*, and *BCRP* mRNA expression levels. Each *dot* represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding *p* value. Both the *x*- and *y*-axis have a logarithmic scale trim(*X*)\* indicates that the 2.5% smallest and largest values of *X* have been shrinked; *r*, Spearman rank correlation coefficient; and *p*, *p* value. The results show a significant positive correlation between *MDR1* and *BCRP* mRNA expression as illustrated by the *p* value and correlation coefficient. In addition, *MRP1* and *LRP* are highly associated. *BCRP* shows a negative correlation with *MRP1* and *LRP*

To assess the clinical relevance of the four resistance genes, their expression was evaluated with regard to CR rate and survival data, respectively. The median follow-up of the 25 patients still alive was 58 months (range, 1--80 months). Univariate logistic regression analysis showed that higher *MDR1* mRNA expression predicted for a lower CR rate (log\[*MDR1*\]: odds ratio \[OR\]=0.75, 95% confidence interval \[CI\] 0.61--0.93, *p* = 0.009), whereas *MRP1*, *LRP*, and *BCRP* mRNA were not associated with CR (Fig. [1](#Fig1){ref-type="fig"}). *MDR1* expression was also associated with a worse EFS (log\[*MDR1*\]: hazard ratio \[HR\]=1.14, 95% CI 1.03--1.27, *p* = 0.01) and OS (log\[*MDR1*\]: HR = 1.16, 95% CI 1.05--1.29, *p* = 0.004). Similar results were also obtained for *MDR1*/*BCRP* coexpression (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). When the analyses were performed with adjustment for other prognostic factors, as described in the "[Statistical analysis](#Sec7){ref-type="sec"}", only *MDR1*/*BCRP* mRNA coexpression remained significantly associated with a lower CR rate (OR = 0.37, 95% CI 0.15--0.91, *p* = 0.03), whereas a trend was observed for worse EFS (Table [3](#Tab3){ref-type="table"}). On the other hand, higher CD34 expression was significantly associated with a lower CR rate (square root\[CD34\]: OR = 0.86, 95% CI 0.76--0.98, *p* = 0.02) and with worse EFS (HR = 1.12, 95% CI 1.06--1.19, *p* \< 0.001), DFS (HR = 1.19, 95% CI 1.09--1.30, *p* \< 0.001), and OS (HR = 1.17, 95% CI = 1.10--1.25, *p* \< 0.001). Table 3Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS CR rateEFSDFSOSOR95% CI*p*HR95% CI*p*HR95% CI*p*HR95% CI*pMDR1* Univariate0.750.61--0.930.0091.141.03--1.270.011.130.97--1.300.111.161.05--1.290.004 Adjusted0.770.58--1.030.081.050.91--1.210.480.950.77--1.180.671.000.87--1.160.97*MRP1* Univariate1.060.83--1.350.631.020.90--1.150.791.070.89--1.290.471.110.97--1.260.12 Adjusted1.220.90--1.660.201.000.87--1.150.981.120.92--1.370.261.050.91--1.210.54*LRP* Univariate1.160.94--1.430.160.950.86--1.060.360.980.84--1.140.790.970.87--1.080.60 Adjusted1.220.93--1.610.150.990.87--1.120.831.060.89--1.270.520.980.86--1.120.78*BCRP* Univariate0.840.66--1.060.141.040.91--1.180.580.950.77--1.160.600.960.84--1.100.58 Adjusted0.790.59--1.060.120.990.86--1.140.920.840.66--1.060.140.900.77--1.050.19*MDR1*/*BCRP* co-expression Univariate0.380.18--0.800.011.631.11--2.370.011.650.90--3.010.111.471.00--2.160.05 Adjusted0.370.15--0.920.031.530.98--2.380.061.370.67--2.820.391.160.74--1.830.51Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34^+^ (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes *MDR1*, *MRP1*, *LRP*, and *BCRP* (natural logarithm of mRNA expression levels) and for *MDR1*/*BCRP* co-expression.Fig. 2Survival of elderly AML patients with and without coexpression of *MDR1* and *BCRP mRNA*. **a** Event-free survival, **b** disease-free survival, **c** overall survival. *pos* indicates patients with coexpression of *MDR1* and *BCRP*; and *other*, patients without coexpression

Discussion {#Sec9}
==========

This is the first comprehensive analysis of the effect of the major classical MDR genes in a cohort of elderly patients with AML homogeneously treated in a prospective clinical trial \[[@CR14]\]. A wide range of expression of the various resistance genes was observed, consistent with previous studies and with comparable median values \[[@CR9]--[@CR11], [@CR23]\]. Our results show that *MRP1*, *LRP*, and *BCRP* are not associated with CR rate or survival endpoints in patients with AML aged 60 years or older, indicating that the clinical relevance of the expression of these genes is limited in this patient population. This study confirms previous reports, which showed the unique prognostic role of MDR1 expression---which was however highly correlated with CD34 expression---in drug resistance in elderly AML (Table [3](#Tab3){ref-type="table"}), in contrast to the prognostic value of MRP1 expression in AML, which has shown conflicting results, whereas currently, LRP is no longer thought to be important for clinical drug resistance \[[@CR4], [@CR5], [@CR7], [@CR24]--[@CR27]\]. Recently, two studies in, respectively, 40 and 31 adult AML patients showed no effect of *BCRP* gene expression on CR rate, whereas OS was lower in patients with the highest *BCRP* expression \[[@CR10], [@CR23]\]. Damiani et al. \[[@CR28]\] showed that *BCRP* expression did not influence achievement of complete remission in AML patients with a median age of 53 years and normal karyotype, however, *BCRP* expression was associated with higher relapse rate. In 59 children with de novo AML, a higher *BCRP* expression was observed in patients who did not reach CR, but this was not translated in poorer survival \[[@CR29]\]. Benderra et al. \[[@CR19]\] indicated that *BCRP* gene expression was an adverse prognostic factor for CR in a group of 149 relatively younger adult AML patients but only in patients treated with DNR and MXT and not with idarubicin. In our cohort of elderly AML patients who were all treated with DNR, whereas MXT was given as consolidation therapy after reaching CR, a significant correlation of *BCRP* mRNA expression with lower CR rate could not be shown.

Our study confirms that *BCRP* and *MDR1* are coexpressed in AML patients with higher age as has been suggested previously from studies in smaller groups of relatively younger AML patients \[[@CR9]--[@CR11], [@CR28]\]. Until now, only two studies have evaluated the clinical value of coexpression of *MDR1* and *BCRP* in a sufficient number, although relatively younger adult AML patients \[[@CR19], [@CR28]\]. Benderra et al. \[[@CR19]\] showed that CR rate was only 45% in the patients with coexpression of *BCRP* and *MDR1* (+/+) in comparison with 66% in the *MDR1*/*BCRP*−/+ and +/−group and 90% in the *MDR1/BCRP*−/−group (*p* = 0.003). Moreover, a significantly lower DFS and OS were found in the *MDR1*/*BCRP*+/+group. Damiani et al. \[[@CR28]\] found a trend towards a higher relapse rate in the small group of *BCRP*+/*MDR1*+patients, indicating that this represents a robust resistant AML phenotype, consistent with our findings in elderly AML. The recent finding that *BCRP* and *MDR1* expression was mainly found in the most resistant group of AML, using gene expression profiling, underscores the role of these drug resistance genes in AML \[[@CR30]\].

However, this study shows, that the prominent prognostic role of CD34 expression in elderly AML should be emphasized, as higher CD34 expression was adversely associated with all clinical endpoints. *MDR1* and *BCRP* but not *MRP1* and *LRP* mRNA expression were found to be associated with high CD34 expression in these elderly AML patients, which may explain why *MDR1* was no longer significant for CR rate, EFS, and OS when adjusted for other prognostic variables including CD34. In the past, MDR1 expression has been linked to the CD34-positive hematopoietic stem cell compartment of the leukemia subtype. In two other studies in younger AML patients, no overexpression (on mRNA and protein level) of *BCRP* in the CD34-positive blast population of clinical AML samples was found \[[@CR13], [@CR19]\]. In contrast, earlier studies in mice demonstrated high levels of *BCRP* and *MDR1* expression in normal hematopoietic stem cells \[[@CR31]--[@CR34]\]. Previously, *BCRP* expression in subsets of stem cells has been reported, indicating that high *BCRP* expression may exist in CD34^+^/CD38^−^ cells or in CD34^+^/CD33^−^cells \[[@CR12], [@CR35]\]. The differential expression of *BCRP* and *MDR1* in specific subsets of hematopoietic stem cells is consistent with the side population phenotype as proposed by Goodell et al. \[[@CR36]\] who claim that BCRP expression can be separated from those expressing the other ABC proteins. This would suggest that BCRP is expressed in even less differentiated hematopoietic stem cells than MDR1 \[[@CR19]\]. In our study in AML, these immature subsets could not be separately investigated, however, the unique *BCRP/MDR1*+/+subgroup of patients reflects an immature leukemic cell type that has a very resistant phenotype in vivo, illustrated by a low CR rate and poor outcome (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).

This is the first study in which a correlation was found between secondary AML and a high expression of *BCRP* mRNA but not the other resistance proteins. In addition to our previous report that *BCRP* is frequently upregulated in patients with AML at relapse, we now demonstrate that expression of *BCRP* is representative of secondary AML, which is especially observed in elderly patients \[[@CR11], [@CR29]\]. Recently, Ross \[[@CR37]\] suggested that MDR modifiers may be of benefit for patients with multiple dysplastic features. This may suggest that *BCRP* is upregulated in diseases in which exposure to xenobiotics during life plays an etiologic role.

We conclude that coexpression of CD34-related coexpression of *MDR1* and *BCRP* reflects a clinically resistant subgroup of elderly AML. In this age group, only *BCRP* is correlated with secondary AML. As such, the development of new treatment strategies for elderly AML patients may focus on modulation of drug resistance targeting both *BCRP* and *MDR1*.
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